News
IRWD
0.7189
+4.64%
0.0319
Weekly Report: what happened at IRWD last week (0707-0711)?
Weekly Report · 2d ago
Ironwood Pharmaceuticals Dismisses Ernst & Young Over Internal Control Weaknesses
Reuters · 6d ago
Weekly Report: what happened at IRWD last week (0630-0704)?
Weekly Report · 07/07 09:11
Ardelyx: 'Hold' With Caution As Major Inflection Point Approaches
Seeking Alpha · 07/03 17:05
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28%
Simply Wall St · 06/25 11:48
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 06/17 21:06
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 06/13 21:05
Ironwood Pharma Elects Directors at Annual Meeting
TipRanks · 06/12 21:16
Weekly Report: what happened at IRWD last week (0602-0606)?
Weekly Report · 06/09 09:12
Ironwood Pharma Receives Nasdaq Deficiency Letter
TipRanks · 06/03 20:36
Weekly Report: what happened at IRWD last week (0526-0530)?
Weekly Report · 06/02 09:13
Weekly Report: what happened at IRWD last week (0519-0523)?
Weekly Report · 05/26 09:13
Weekly Report: what happened at IRWD last week (0512-0516)?
Weekly Report · 05/19 09:12
Medicare to publish drugs selected for third round of price negotiations by Feb. 1
Seeking Alpha · 05/13 12:11
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), LENZ Therapeutics (LENZ) and Ironwood Pharma (IRWD)
TipRanks · 05/12 12:40
Weekly Report: what happened at IRWD last week (0505-0509)?
Weekly Report · 05/12 09:12
Ironwood Pharmaceuticals Reports Q1 2025 Financial Results
TipRanks · 05/09 04:22
Ironwood Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 05/07 13:32
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Codexis (CDXS) and Ironwood Pharma (IRWD)
TipRanks · 05/07 13:20
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/07 12:20
More
Webull provides a variety of real-time IRWD stock news. You can receive the latest news about Ironwood through multiple platforms. This information may help you make smarter investment decisions.
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.